Market Overview

GlycoMimetics to Present at Upcoming Investor Conferences


GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive
Officer Rachel King will provide a company overview at two upcoming
investor conferences, as follows:

When: November 13,
2018 at 10:15 a.m. ET
Where: New York, NY, USA

When: November
15, 2018 at 8:40 a.m. GMT
Where: London, UK

To access the live webcast and subsequent archived recordings for the
presentations, please visit the GlycoMimetics website at

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate,
GMI-1271 (uproleselan), an E-selectin antagonist, was evaluated in a
Phase 1/2 clinical trial as a potential treatment for AML and is
currently being evaluated in a Phase 1 clinical trial for the treatment
of multiple myeloma. The FDA granted uproleselan Breakthrough Therapy
designation for the treatment of adult acute myeloid leukemia (AML)
patients with relapsed/refractory disease. GlycoMimetics is also
conducting a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at

View Comments and Join the Discussion!